drugset
drugset / Trial / NCT02080364

Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease

NCT02080364 ↗

Phase 3 Terminated 880 enrolled vTv Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 18 months.

Timeline

Start
2015-04
Primary completion
2018-06-01
Completion
2018-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Azeliragon Small molecule 5 mg Oral

Indications

Alzheimer disease